Branding Protein RNA 
STAT News
JULY 19, 2022
The vaccine is a recombinant protein product, developed with the same kind of approach that is used for a brand of flu vaccine. Some people who have refused Covid vaccines have expressed hesitancy over the messenger RNA vaccines produced by Moderna and the Pfizer and BioNTech partnership. Read the rest…
The Pharma Data
JANUARY 22, 2021
As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 6, 2021
Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. At the same time, the Group aims to increase its earning power and create value through innovation and growth. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5
Roots Analysis
JANUARY 28, 2024
Not only in healthcare, but various industries have also adopted big data to enhance their capabilities, improve customer experiences, and strengthen their brand reputation, thereby contributing to overall growth of the company. This project highlights her ability to navigate the complex intersection of science and finance.
XTalks
AUGUST 30, 2022
Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. Biogen’s nusinersen (brand name Spinraza) is an antisense oligonucleotide (ASO) therapy that is administered directly into the CNS by intrathecal injection through lumbar puncture.
Pharmaceutical Technology
OCTOBER 28, 2022
To demonstrate bioequivalence for a generic small molecule drug, a company must carry out a Phase I clinical trial in healthy individuals to ensure that the area under the curve and maximum plasma concentration for their drug is equivalent to that of the brand name drug. For more information, please download our white paper.
The Pharma Data
AUGUST 30, 2021
As the first and only small interfering RNA to provide effective and sustained LDL-C reduction, Leqvio helps manage a critical cardiovascular risk factor for ASCVD. Leqvio is the first and only approved small interfering RNA (siRNA) LDL-C-lowering treatment in Europe 6,7. Product and brand name are currently under FDA review.
Expert insights. Personalized for you.
98 
Let's personalize your content